- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
- Device · Drug · Other + 2 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 133
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
- Interventions
- Amyvid PET Scan, T807 PET scan
- Drug
- Lead sponsor
- Samuel Gandy
- Other
- Eligibility
- 40 Years to 85 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- [C-11]PiB-PET/MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
- Interventions
- F-18 AV 1451, C-11 PiB
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- [18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
- Drug · Diagnostic Test
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Alzheimer's Disease
- Interventions
- Florbetaben
- Drug
- Lead sponsor
- Yaakov Stern
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Alzheimer Dementia
- Interventions
- Blood collection, PiB PET/MRI, and cognitive testing
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1,122 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Tauopathies
- Interventions
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease, Cognitive Decline
- Interventions
- [18F]AV-1451, Positron Emission Tomography
- Drug · Procedure
- Lead sponsor
- Neil M Rofsky, MD, MHA
- Other
- Eligibility
- 38 Years to 96 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Interventions
- [18F]Flutemetamol
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
- Interventions
- 18F-AV-1451
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
- Interventions
- C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
- Diagnostic Test
- Lead sponsor
- Jennifer Whitwell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
- Interventions
- PET Biomarker Disclosure
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration
- Interventions
- Flortaucipir F18, Brain PET scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
- Conditions
- Mild Cognitive Impairment, Healthy Aging
- Interventions
- Personalized DAT Risk Disclosure Protocol
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Normal Pressure Hydrocephalus
- Interventions
- [18F] Flutemetamol
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- florbetapir F 18, [11C]-PIB
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- F 18 T807 Flortaucipir
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease
- Interventions
- [18F]NAV4694
- Drug
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Elk Grove Village, Illinois + 4 more
- Conditions
- Brain Fibrillarab Levels
- Interventions
- [18F] Flutemetamol
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, 18F-Florbetaben
- Drug
- Lead sponsor
- Adam Brickman
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Transthyretin Amyloidosis
- Interventions
- I 124-Evuzamitide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years to 105 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- Florbetapir (18F), 11C-PiB
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Transcranial Alternating Current Stimulation (tACS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts